elminda’s BNA™ platform has been at the center of several collaborations with major pharmaceutical companies involved in CNS drug development.
A joint study performed by elminda and scientists from the University of Toronto, Canada and from the Ben-Gurion University of the Negev, Israel, serves as an example demonstrating the potential use of the BNA™ product in detecting and quantifying drug-induced neural response and changes in brain network activity.
The study investigated BNA™ as a tool for objective and sensitive monitoring of cognitive changes induced by therapeutic interventions.
Scopolamine, a muscarinic receptor antagonist compound was used to induce a reversible cognitive decline in healthy volunteers, simulating Alzheimer’s Disease (AD), in a double blind placebo controlled study design. Muscarinic receptor antagonist is often used as a pharmacological model for Alzheimer’s Disease (AD)-related cognitive deficits, due its adverse effects on cognitive functions such as attention and short-term memory (STM) in healthy control subjects.
elminda’s BNA™ technology was used to objectively evaluate electrophysiological responses and compare BNAs patterns following Scopolamine and placebo administration.
The BNA™ technology revealed activity networks with significant difference between the drug and Placebo. Additionally, the BNA™ analyses revealed that the drug substantially reduced the connectivity within specific sub-networks.
 Wesnes et al., 1988; Robbins et al., 1997; Schon et al., 2005; Mintzer and Griffiths 2007; Lenz et al., 2012